Which Patients Will Benefit from Immunotherapy for Cancer? Some Hints Emerge

Researchers have identified a “genetic signature” in the tumors of patients with advanced melanoma who responded to a form of immunotherapy called checkpoint blockade. The results could be the basis for a test that identifies likely responders to this treatment as well as for developing new treatments.

Source link

Comments are closed.